ClinicalTrials.gg
CompletedNCT01685892Updated Jan 10, 2020

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

A Phase 1 interventional study of Obinutuzumab and Venetoclax in Lymphocytic Leukemia, Chronic, sponsored by Genentech, Inc.. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-10.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2018, 8 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell — 16 open to participants now, 28 under way, 6 of them phase 3. obinutuzumab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
22nd of 53
82 · median 72
Started
2012
the only one that year
Phase 1
7 of 53
1 open now
Registered
4th of 53
by date
Lead sponsor
5 of 53
Genentech, Inc.

Among the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 22nd largest by enrollment, is the only one that started in 2012, is one of 7 in phase 1, and was the 4th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

16 of the 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About obinutuzumab

obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing obinutuzumab in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics as well as the preliminary efficacy of venetoclax (GDC-0199; ABT-199) administered in combination with obinutuzumab to participants with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL). The study is comprised of two stages for each participant population: a dose-finding stage and a safety-expansion stage. The dose-finding stage will explore multiple doses of venetoclax to be used in combination with a fixed dose of obinutuzumab. The dose-finding stage will also explore two schedules for drug administration, Schedule A (venetoclax introduced before obinutuzumab) and Schedule B (venetoclax introduced after obinutuzumab).

03

Conditions studied

  • Lymphocytic Leukemia, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of relapsing/ or previously untreated chronic lymphocytic leukemia
  • (ECOG) performance score of less than or equal to (\</=) 1
  • Adequate bone marrow function
  • Adequate coagulation, renal and hepatic function
  • For all participants, agreement to remain abstinent or use methods that result in a failure rate of less than (\<) 1% per year during the treatment period and for at least 90 days (30 days for women) after the last dose of venetoclax or 18 months after the last dose of obinutuzumab, whichever is longer

Exclusion criteria

Exclusion Criteria:

  • Participants who have undergone allogenic stem cell transplant are ineligible unless they meet the following criteria, a) participants who are off all therapy, b) participants who have no signs and/or symptoms of acute or chronic , or c) participants must have appropriate hematology counts
  • Infection with (HIV), , or
  • Uncontrolled hemolytic anemia or thrombocytopenia
  • or anti-cancer therapy within 5 half-lives prior to the first dose of study drug
  • History of significant renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Dose-Finding: Schedule A: Relapsed/Refractory CLL

    All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.

    Drug: Obinutuzumab · Drug: Venetoclax

  • Experimental
    Dose-Finding: Schedule B: Relapsed/Refractory CLL

    In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.

    Drug: Obinutuzumab · Drug: Venetoclax

  • Experimental
    Dose-Finding: Schedule A: Previously Untreated CLL

    All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.

    Drug: Obinutuzumab · Drug: Venetoclax

  • Experimental
    Dose-Finding: Schedule B: Previously Untreated CLL

    In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.

    Drug: Obinutuzumab · Drug: Venetoclax

  • Experimental
    Safety Expansion: Relapsed/Refractory CLL

    In participants with relapsed/refractory CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.

    Drug: Obinutuzumab · Drug: Venetoclax

  • Experimental
    Safety Expansion: Previously Untreated CLL

    In participants with previously untreated CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.

    Drug: Obinutuzumab · Drug: Venetoclax

Interventions

  • Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.

    Also known as: GA101; RO5072759

  • Participants will receive multiple doses of venetoclax orally once daily.

    Also known as: ABT-199, GDC-0199

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Dose Limiting Toxicities (DLTs)

    Time frame: Schedule (Sch) A (Cycle 1 Day 1 to Day 21), Sch B (Cycle 1 Day 22 to Cycle 2 Day 28) (1 Cycle=28 days)

  2. Maximum Tolerated Dose (MTD) of Venetoclax in Combination with Obinutuzumab

    Time frame: Sch A (Cycle 1 Day 1 to Day 21), Sch B (Cycle 1 Day 22 to Cycle 2 Day 28) (1 Cycle=28 days)

Secondary outcomes

  1. Percentage of Participants with Adverse Events

    Time frame: Baseline up to end of study (up to approximately 5 years and 5 months)

  2. Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) to Obinutuzumab

    Time frame: Baseline up to Cycle 6 (1 Cycle=28 days)

  3. Area Under the Concentration-Time Curve (AUC) of Venetoclax

    Time frame: Baseline up to Cycle 6 (1 Cycle=28 days)

  4. Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax

    Time frame: Baseline up to Cycle 6 (1 Cycle=28 days)

  5. Maximal Plasma Concentration (Cmax) of Venetoclax

    Time frame: Baseline up to Cycle 6 (1 Cycle=28 days)

  6. Minimum Plasma Concentration (Cmin) of Venetoclax

    Time frame: Baseline up to Cycle 6 (1 Cycle=28 days)

  7. Cmax of Obinutuzumab

    Time frame: Baseline up to Cycle 6 (1 Cycle=28 days)

  8. Cmin of Obinutuzumab

    Time frame: Baseline up to Cycle 6 (1 Cycle=28 days)

  9. Percentage of Participants with Confirmed Complete Response (CR) as Determined by Standard CLL Response Criteria

    Time frame: Baseline up to end of study (up to approximately 5 years and 5 months)

  10. Percentage of Participants with Objective Response (Partial Response [PR] or CR [Including Cytopenic CR] as Determined by Standard CLL Response Criteria

    Time frame: Baseline up to end of study (up to approximately 5 years and 5 months)

  11. Duration of Objective Response as Determined by Standard CLL Response Criteria

    Time frame: Baseline up to end of study (up to approximately 5 years and 5 months)

  12. Overall Survival

    Time frame: Baseline up to death or end of study (up to approximately 5 years and 5 months)

  13. Progression-Free Survival as Determined by Standard CLL Response Criteria

    Time frame: Baseline up to end of study (up to approximately 5 years and 5 months)

  14. Change from Baseline in Number of B-Cells

    Time frame: Baseline up to end of study (up to approximately 5 years and 5 months)

  15. Change from Baseline in Number of T-Cells

    Time frame: Baseline up to end of study (up to approximately 5 years and 5 months)

  16. Change from Baseline in Number of Natural Killer (NK) Cells

    Time frame: Baseline up to end of study (up to approximately 5 years and 5 months)

  17. Change from Baseline in Serum Immunoglobulin Level

    Time frame: Baseline up to end of study (up to approximately 5 years and 5 months)

07

Study locations

10 sites
  • UCSD Moores Cancer Center
    La Jolla, California 92093, United States
  • Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center
    Denver, Colorado 80218, United States
  • Weill Cornell Medical College-New York Presbyterian Hospital
    New York, New York 10021, United States
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Oncology Associates of Oregon
    Springfield, Oregon 97477, United States
  • SCRI-Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • The Methodist Hospital Research Institute; Academic Office of Clinical Trials
    Houston, Texas 77030, United States
  • St James University Hospital
    Leeds, LS9 7TF, United Kingdom
  • Leicester Royal Infirmary NHS Trust
    Leicester, LE1 5WW, United Kingdom
  • Barts and The London School of Medicine and Dentistry; Queen Mary, University of London
    London, E1 2AD, United Kingdom
08

References and documents

Publications

  • Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12. PubMed 30862645 ↗
  • Samineni D, Gibiansky L, Wang B, Vadhavkar S, Rajwanshi R, Tandon M, Sinha A, Al-Sawaf O, Fischer K, Hallek M, Salem AH, Li C, Miles D. Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial. Adv Ther. 2022 Aug;39(8):3635-3653. doi: 10.1007/s12325-022-02170-w. Epub 2022 Jun 16. PubMed 35708885 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in May 2018, 65 months.

Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 65 months is above that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2012
First posted
Sep 14, 2012
StartActual
Nov 29, 2012
Primary completionActual
May 21, 2018
CompletionActual
Aug 23, 2019
Last update
Jan 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01685892
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Sep 14, 2012
Start date
Nov 29, 2012
Primary completion
May 21, 2018
Completion
Aug 23, 2019
Last update
Jan 10, 2020

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Obinutuzumab · Venetoclax

Start the discussion